The size of the Prostate Cancer Market in Europe was valued at USD 16.69 billion in 2020 and estimated to be growing at a CAGR of 9.1%, to reach USD 25.8 billion by 2025. Market access restrictions to high-cost agents for prostate cancer are increasingly influential in European markets.
Prostate cancer is a commercially profitable indication with a high amount of diagnosis incidences. The drug treatment of prostate cancer has evolved quickly over the last few years, with the metastatic castrate-resistant prostate cancer (mCRPC) situation becoming more crowded and competitive.
The rising incidence of prostate cancer is recognized as a major driver for the growth of the prostate cancer market during the forecast period. Some other drivers are the increasing geriatric population base, growing demand for novel drugs, and the existence of high unmet needs. Factors restraining market growth include high treatment costs and low patient compliance due to complicated treatment methods.
This research report on the Europe Prostate Cancer Market has been segmented and sub-segmented into the following categories.
By Diagnostic Techniques:
By Surgery:
By Radiation Therapy:
By Chemotherapy:
By Country:
Some of the promising companies dominating the Europe Prostate Cancer Market Profiled in the Report are Sanofi S.A, GlaxoSmithKline, AstraZeneca, AbbVie, Varian Medical Systems, Elekta, Theragenics, Pfizer, Novartis, Roche, Bayer, Johnson & Johnson, Abbott Laboratories, and Genentech, etc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Diagnostic Techniques
5.1.1 Introduction
5.1.2 Digital Rectal Exam (DRE)
5.1.3 Prostate Specific Antigen Test (PSA)
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2 Surgery
5.2.1 Introduction
5.2.2 Radical Prostatectomy
5.2.3 Orchidectomy
5.2.4 Trans Urethral Resection (TUR)
5.2.5 Y-o-Y Growth Analysis, By Type
5.2.6 Market Attractiveness Analysis, By Type
5.2.7 Market Share Analysis, By Type
5.3 Radiation Therapy
5.3.1 Introduction
5.3.2 External Beam Radiation Therapy
5.3.2.1 3D Conformal Radiation Therapy
5.3.2.2 Intensity Modulated Radiation Therapy
5.3.2.3 Stereotactic Body Radiation Therapy
5.3.2.4 Proton Beam Radiation Therapy
5.3.3 Brachytherapy
5.3.3.1 Permanent Brachytherapy
5.3.3.2 Temporary Brachytherapy
5.3.4 Y-o-Y Growth Analysis, By Application
5.3.5 Market Attractiveness Analysis, By Application
5.3.6 Market Share Analysis, By Application
5.4 Chemotherapy
5.4.1 Introduction
5.4.2 Docetaxel
5.4.3 Etoposide
5.4.4 Vinblastine
5.4.5 Carboplatin
5.4.6 Vinorelbine
5.4.7 Y-o-Y Growth Analysis, By Disease Indications
5.4.8 Market Attractiveness Analysis, By Disease Indications
5.4.9 Market Share Analysis, By Disease Indications
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Diagnostic Techniques
6.1.3.3 By Surgery
6.1.3.4 By Radiation Therapy
6.1.3.5 By Chemotherapy
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Diagnostic Techniques
6.1.4.3 By Surgery
6.1.4.4 By Radiation Therapy
6.1.4.5 By Chemotherapy
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Diagnostic Techniques
6.1.5.3 By Surgery
6.1.5.4 By Radiation Therapy
6.1.5.5 By Chemotherapy
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Sanofi S.A
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 GlaxoSmithKline
8.3 AstraZeneca
8.4 AbbVie
8.5 Varian Medical Systems
8.6 Elekta
8.7 Theragenics
8.8 Pfizer
8.9 Novartis
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020